Testing two study drugs for advanced lung cancer and other tumors
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old, and your expected survival is at least 3 months
- You have a confirmed advanced or metastatic solid tumor (like non-small cell lung cancer or nasopharyngeal cancer)
- You have at least one measurable tumor spot on scans (per RECIST 1.1) and you can share tumor tissue
- You’re well enough to do daily activities (ECOG 0–1) and any side effects from prior treatment are mild (back to grade 1 or less)
- Your heart function is acceptable (left heart pumping strength, called ejection fraction, is at least 50%)
- Your blood tests and organ health meet study limits, including acceptable clotting tests and kidney/urine protein limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
This Phase 1 trial tests BL-B01D1 in people with advanced or metastatic solid tumors that are not curable or lack standard treatment options. The goal is to see how the drug works in the body and whether it’s safe enough to study further.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.